These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies. Adedokun OJ; Xu Z; Marano CW; Strauss R; Zhang H; Johanns J; Zhou H; Davis HM; Reinisch W; Feagan BG; Rutgeerts P; Sandborn WJ J Crohns Colitis; 2017 Jan; 11(1):35-46. PubMed ID: 27440869 [TBL] [Abstract][Full Text] [Related]
8. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy. Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209 [TBL] [Abstract][Full Text] [Related]
9. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis. Carbonnel F; Colombel JF; Filippi J; Katsanos KH; Peyrin-Biroulet L; Allez M; Nachury M; Novacek G; Danese S; Abitbol V; Bossa F; Moreau J; Bommelaer G; Bourreille A; Fumery M; Roblin X; Reinisch W; Bouhnik Y; Brixi H; Seksik P; Malamut G; Färkkilä M; Coulibaly B; Dewit O; Louis E; Deplanque D; Michetti P; Sarter H; Laharie D; ; Gastroenterology; 2016 Feb; 150(2):380-8.e4. PubMed ID: 26632520 [TBL] [Abstract][Full Text] [Related]
10. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Panaccione R; Ghosh S; Middleton S; Márquez JR; Scott BB; Flint L; van Hoogstraten HJ; Chen AC; Zheng H; Danese S; Rutgeerts P Gastroenterology; 2014 Feb; 146(2):392-400.e3. PubMed ID: 24512909 [TBL] [Abstract][Full Text] [Related]
11. Initial experience with golimumab in clinical practice for ulcerative colitis. Castro-Laria L; Argüelles-Arias F; García-Sánchez V; Benítez JM; Fernández-Pérez R; Trapero-Fernández AM; Gallardo-Sánchez F; Pallarés-Manrique H; Gómez-García M; Cabello-Tapia MJ; Talavera-Fabuel A; Bejarano-García A; Leo-Carnerero E; Hernández-Martínez Á; Caunedo-Álvarez Á; Herrerías-Gutiérrez JM Rev Esp Enferm Dig; 2016 Mar; 108(3):129-32. PubMed ID: 26786341 [TBL] [Abstract][Full Text] [Related]
12. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study. Bosca-Watts MM; Cortes X; Iborra M; Huguet JM; Sempere L; Garcia G; Gil R; Garcia M; Muñoz M; Almela P; Maroto N; Paredes JM World J Gastroenterol; 2016 Dec; 22(47):10432-10439. PubMed ID: 28058024 [TBL] [Abstract][Full Text] [Related]
13. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Peyrin-Biroulet L; Hart A; Bossuyt P; Long M; Allez M; Juillerat P; Armuzzi A; Loftus EV; Ostad-Saffari E; Scalori A; Oh YS; Tole S; Chai A; Pulley J; Lacey S; Sandborn WJ; Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):128-140. PubMed ID: 34798039 [TBL] [Abstract][Full Text] [Related]
14. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Feagan BG; Sands BE; Sandborn WJ; Germinaro M; Vetter M; Shao J; Sheng S; Johanns J; Panés J; Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):307-320. PubMed ID: 36738762 [TBL] [Abstract][Full Text] [Related]
15. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Vermeire S; Sandborn WJ; Danese S; Hébuterne X; Salzberg BA; Klopocka M; Tarabar D; Vanasek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hinz M; Ahmad A; Pradhan V; Hassan-Zahraee M; Clare R; Cataldi F; Reinisch W Lancet; 2017 Jul; 390(10090):135-144. PubMed ID: 28527704 [TBL] [Abstract][Full Text] [Related]
16. Maintenance therapy with certolizumab pegol for Crohn's disease. Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ; N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459 [TBL] [Abstract][Full Text] [Related]
17. Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension. Reinisch W; Gibson PR; Sandborn WJ; Feagan BG; Strauss R; Johanns J; Padgett L; Adedokun OJ; Colombel JF; Collins J; Rutgeerts P; Tarabar D; Marano C J Crohns Colitis; 2018 Aug; 12(9):1053-1066. PubMed ID: 29917070 [TBL] [Abstract][Full Text] [Related]
18. Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis. Detrez I; Dreesen E; Van Stappen T; de Vries A; Brouwers E; Van Assche G; Vermeire S; Ferrante M; Gils A J Crohns Colitis; 2016 May; 10(5):575-81. PubMed ID: 26738756 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study. Croft NM; Faubion WA; Kugathasan S; Kierkus J; Ruemmele FM; Shimizu T; Mostafa NM; Venetucci M; Finney-Hayward T; Sanchez Gonzalez Y; Bereswill M; Lazar A; Turner D Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):616-627. PubMed ID: 34153231 [TBL] [Abstract][Full Text] [Related]
20. Vedolizumab as induction and maintenance therapy for ulcerative colitis. Feagan BG; Rutgeerts P; Sands BE; Hanauer S; Colombel JF; Sandborn WJ; Van Assche G; Axler J; Kim HJ; Danese S; Fox I; Milch C; Sankoh S; Wyant T; Xu J; Parikh A; N Engl J Med; 2013 Aug; 369(8):699-710. PubMed ID: 23964932 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]